N/A
Completed N=69
Clareon PanOptix Pro vs. Clareon PanOptix - Study B
Aphakia · Presbyopia
Source: ClinicalTrials.gov NCT06401551 ↗
Enrolled (actual)
69
Serious AEs
1.1%
Results posted
Jan 2026
Primary outcomePrimary: Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) — -0.016; 0.010 logMAR
Summary
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) |
-0.016; 0.010 | — |
Eligibility Criteria
Key Inclusion Criteria
- Understand and sign an ethics committee-approved informed consent form;
- Willing and able to attend all scheduled study visits as required by the protocol;
- Planned cataract surgery (both eyes);
- Preoperative corneal astigmatism less that 1.00 diopter in each eye.
- Other protocol-defined inclusion criteria may apply.
Key Exclusion Criteria
- Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding;
- Ocular conditions as specified in the protocol;
- Subjects who desire monovision correction.
- Other protocol-defined exclusion criteria may apply.
Data sourced from ClinicalTrials.gov (NCT06401551). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.